全文获取类型
收费全文 | 52369篇 |
免费 | 4986篇 |
国内免费 | 1260篇 |
专业分类
耳鼻咽喉 | 709篇 |
儿科学 | 2331篇 |
妇产科学 | 589篇 |
基础医学 | 4654篇 |
口腔科学 | 927篇 |
临床医学 | 5446篇 |
内科学 | 6969篇 |
皮肤病学 | 572篇 |
神经病学 | 2885篇 |
特种医学 | 835篇 |
外国民族医学 | 3篇 |
外科学 | 3307篇 |
综合类 | 9085篇 |
现状与发展 | 5篇 |
一般理论 | 1篇 |
预防医学 | 5520篇 |
眼科学 | 649篇 |
药学 | 3989篇 |
57篇 | |
中国医学 | 8977篇 |
肿瘤学 | 1105篇 |
出版年
2024年 | 183篇 |
2023年 | 1090篇 |
2022年 | 1808篇 |
2021年 | 2913篇 |
2020年 | 2785篇 |
2019年 | 2104篇 |
2018年 | 2063篇 |
2017年 | 2206篇 |
2016年 | 2289篇 |
2015年 | 1919篇 |
2014年 | 3953篇 |
2013年 | 3799篇 |
2012年 | 3328篇 |
2011年 | 3413篇 |
2010年 | 2640篇 |
2009年 | 2191篇 |
2008年 | 2074篇 |
2007年 | 2123篇 |
2006年 | 1849篇 |
2005年 | 1532篇 |
2004年 | 1343篇 |
2003年 | 1300篇 |
2002年 | 939篇 |
2001年 | 911篇 |
2000年 | 768篇 |
1999年 | 684篇 |
1998年 | 557篇 |
1997年 | 500篇 |
1996年 | 440篇 |
1995年 | 486篇 |
1994年 | 412篇 |
1993年 | 349篇 |
1992年 | 315篇 |
1991年 | 296篇 |
1990年 | 291篇 |
1989年 | 254篇 |
1988年 | 234篇 |
1987年 | 228篇 |
1986年 | 195篇 |
1985年 | 299篇 |
1984年 | 246篇 |
1983年 | 184篇 |
1982年 | 219篇 |
1981年 | 175篇 |
1980年 | 149篇 |
1979年 | 126篇 |
1978年 | 103篇 |
1977年 | 80篇 |
1976年 | 83篇 |
1974年 | 44篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
111.
Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women 总被引:7,自引:0,他引:7
J. C. Koster W. H. L. Hackeng H. Mulder 《European journal of clinical pharmacology》1996,51(2):145-147
Objective: The effects of vitamin D deficiency in osteopenic postmenopausal women treated with intermittent cyclical etidronate have
been studied. Bone mass and biochemical parameters as bone markers were measured before and after one year of therapy with
intermittent cyclical etidronate.
Results:
In 30 patients without vitamin D deficiency, bone mass in the lumbal spine and femoral neck was significantly increased compared
to 28 vitamin D deficient patients. After cyclical intermittent etidronate therapy, serum osteocalcin and PTH were significantly
increased in the vitamin D deficient patients, whereas in non-vitamin D deficient patients they did not change.
Conclusion:
It is worthwhile measuring serum vitamin D before starting etidronate therapy and, in case of deficiency, to give vitamin
D.
Received: 6 April 1995/Accepted in revised form: 23 April 1996 相似文献
112.
C. J. Bowden W. D. Figg N. A. Dawson O. Sartor R. J. Bitton M. S. Weinberger Donna Headlee Eddie Reed C. E. Myers M. R. Cooper 《Cancer chemotherapy and pharmacology》1996,39(1-2):1-8
Introduction: Suramin is a synthetic polysulfonated naphthylurea which has been used for the treatment of African trypanosomiasis and onchocerciasis,
but since the mid-1980s has received attention as a possible antiretroviral and antineoplastic agent. Objective: This clinical trial of suramin was undertaken as a phase I/II study in patients with hormone-refractory prostate cancer,
with the hypothesis that the intensity of therapy with suramin could be increased significantly if measures were undertaken
to maintain the plasma concentrations of the drug under 300 μg/ml. Methods: We report the clinical results of this trial, wherein patients were treated at three different targeted plasma suramin concentrations
(275, 215 and 175 μg/ml) for varying periods of time (2, 4 or 8 weeks), with delivery of the drug by continuous intravenous
infusion. Results: The major toxicity observed in this trial was neurologic, consisting of a motor and sensory peripheral neuropathy that resulted
in both paresis and paralysis of the limbs. Nearly all of this severe (CTEP grade III, IV) neurologic toxicity was observed
in the patients treated at a plasma suramin concentration of 275 μg/ml for 4 or more weeks. A single patient treated at 215 μg/ml
for 8 weeks developed moderate (CTEP grade III) proximal lower extremity weakness, and no patient treated at 175 μg/ml developed
this toxicity. The second most common toxicity observed was infection of the central venous catheter. The overall response
rate for all of the evaluable patients was 17% (13 of 75 patients). In addition, prostate-specific antigen (PSA)-defined responses
were observed in six patients receiving therapy at 175 μg/ml, but these responses were confounded by cessation of therapy
with flutamide during suramin treatment. Conclusions: In summary, although plasma suramin concentrations were maintained below 300 μg/ml, neurologic toxicity nonetheless occurred
with high frequency in patients treated at 275 μg/ml for 4 or more weeks. Therapy at 215 and 175 μg/ml was in general well
tolerated, but central venous catheter-related infection, as well as the inconvenience and expense of continuous infusional
therapy, make this method of drug delivery impractical. Only moderate antitumor activity was observed during this trial, but
it is possible that both continuation of flutamide and flutamide withdrawal during suramin therapy confounded the assessment
of suramin’s activity in hormone-refractory prostate cancer.
Received: 9 June 1995/Accepted: 18 March 1996 相似文献
113.
目的探讨维生素E对老年小鼠细胞免疫功能及心、脑脂质过氧化反应的影响。方法3月龄幼年小鼠和18月龄老年小鼠各饲以含维生素E(VitE)500×10-6和30×10-6饲料8周后,测定血清VitE水平、脾细胞转化反应和心、脑脂褐质含量。结果饲以含500×10-6VitE饲料的老年小鼠脾细胞对刀豆蛋白A(ConA)和脂多糖(LPS)的反应及血清VitE水平均较饲以含30×10-6VitE饲料者显著增高(P值<0.01);心、脑组织中脂褐质含量则明显降低(分别为P值<0.01及0.05)。结论膳食中补充较高剂量VitE后,能显著提高老年小鼠血清VitE水平,增强脾细胞转化反应,并明显抑制心、脑脂质过氧化,减少脂褐质形成 相似文献
114.
Benign intracranial hypertension and recombinant growth hormone therapy in Australia and New Zealand
PA Crock JD McKenzie AM Nicoll NJ Howard W Cutfield LK Shield G Byrne 《Acta paediatrica (Oslo, Norway : 1992)》1998,87(4):381-386
Benign intracranial hypertension (BIH) is reported in three children from Australia and one from New Zealand, who were being treated with recombinant human growth hormone (rhGH). Three males and one female, aged between 10.5 and 14.2 y, developed intracranial hypertension within 2 weeks to 3 months of starting treatment. A national database, OZGROW, has been prospectively collecting data on all 3332 children treated with rhGH in Australia and New Zealand from January 1986 to 1996. The incidence of BIH in children treated with growth hormone (GH) is small, 1.2 per 1000 cases overall, but appears to be greater with biochemical GHD (<10IUml -1 ), i.e. 6.5/1000 (3 in 465 cases), relative risk 18.4, 95% confidence interval 1.9-176.1, than in all other children on the database. The incidence in patients with Turner's syndrome was 2.3/1000 (1 in 428 cases). No cases in patients with partial GHD (10–20 IUml -1 ) or chronic renal failure were identified. Possible causative mechanisms are discussed. The authors'practice is now to start GH replacement at less than the usual recommended dose of 14IUm-2 week-1 in those children considered to be at high risk of developing BIH. Ophthalmological evaluation is recommended for children before and during the first few months following commencement of rhGH therapy and is mandatory in the event of peripheral or facial oedema, persistent headaches, vomiting or visual symptoms. The absence of papilledema does not exclude the diagnosis. 相似文献
115.
116.
117.
Summary Neurofibromatosis is sometimes complicated by impaired renal tubular reabsorption of phosphate, hypophosphatemia, and osteomalacia.
Hyperparathyroidism has also been reported in patients with neurofibromatosis. When hypercalcemia and elevated levels of parathyroid
hormone are found in osteomalacia, however, it may be difficult to determine if the hyperparathyroidism was primary or tertiary.
We describe a patient with neurofibromatosis, hypercalcemic hyperparathyroidism, hypophosphatemic osteomalacia, vitamin D
deficiency, and clear-cell hyperplasia of all four parathyroid glands. Serial biomechanical, bone biopsy, and densitometric
studies confirmed that treatment with ergocalciferol, calcium, and phosphate supplements significantly improved the osteomalacia
but caused increased parathyroid overactivity. After subtotal parathyroidectomy, the parathyroid hormone concentration became
normal and the bone mineral content increased at the spine and hip, but inappropriate phosphaturia persisted. The findings
indicate that hyperparathyroidism, osteomalacia, and vitamin D deficiency adversely affect each other. 相似文献
118.
目的 :研究SideropenicDysphagla (S -D)综合征膜性蹼产生的机制。方法 :回顾分析S -D综合征2 6例的临床资料。结果 :影像学检查显示膜性蹼在颈段食道前壁呈 2mm深的模样陷凹。血液学检查为缺铁性低血红蛋白性贫血改变。结论 :缺铁性贫血是S -D综合征的原因 ,铁剂治疗有效 相似文献
119.
S. C. Phillips 《Acta neuropathologica》1987,73(2):171-176
Summary Groups of adult male mice were either fed a thiamine-deficient diet for 10 weeks and thereafter treated with ethanol by making them inhale vapourized cane spirit for 10 weeks, or given both treatments simultaneously. The brains of these mice were then searched for degeneration using both light and electron microscopy. No degenerating nerve cells were observed in any animal in the cerebral cortex, hippocampus, cerebellum, olfactory bulbs, midbrain or hindbrain. However, axon terminal degeneration was seen in the olfactory bulbs and deep cerebellar nuclei in mice given the combined treatment. No cerebellar degeneration was found and only little degeneration was present in the olfactory bulbs of mice given the two treatments at different times. Thus, the combined treatment of alcohol and thiamine deficiency produced more brain damage than the sum of that produced by the two treatments given separately. This represents the first experimental in vivo demonstration of a biochemical interaction between these two factors in alcohol-related brain damage. The findings of long-term animal treatment with models using thiamine antagonists are compared.Supported by the special Research Fund Programme of Monash University (Post-Doctoral Fellowship) 相似文献
120.
目的 :了解昆明城区及大理农村 7月~ 7岁儿童目前的铁缺乏水平 ,进一步展开对儿童铁缺乏症的防治 ,降低儿童营养性缺铁性贫血的患病率 .方法 :采用抽样调查的方法对两地 7月~ 7岁儿童共 96 9名进行血清铁蛋白 (SF)、锌原卟啉 (ZPP)、血红蛋白 (Hb)实验室检查 .结果 :7月~ 7岁儿童的总铁缺乏检出率为 2 5 1% ,铁减少检出率为 19 0 % ,贫血患病率为 6 1% ;男女童患病率在 1岁以前差别较大 ,1岁以后差别不明显 ;各年龄组患病率以 7月~ 1岁组最高 ;早产儿、低出生体重儿童患病率相对较高 ;铁缺乏的儿童营养不良的患病率高于正常儿童 .结论 :儿童缺铁性贫血仍要引起重视 .在防治中要抓重点人群 ,除改变膳食结构和饮食习惯 ,对目标人群要适当补充铁剂预防 相似文献